NEFL and myeloid sarcoma: Nonetheless, consistently low NF-L levels were observed in the serum of six Korean patients with MS who achieved a NEDA-3 status over approximately 2 years of follow-up after alemtuzumab treatment, with the majority of samples remaining below the assumed limit of normality (as generated by adding two standard deviations to the mean value of age- and gender-matched control subjects) [29].